The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Seagrass Boutique Hospitality Group

Advising Seagrass Boutique Hospitality Group (“Seagrass”), a Crescent Capital Partners portfolio company, on its sale to Tokyo Stock Exchange listed Colowide Co., Ltd. Seagrass is one of Australia and the UAE’s largest and most successful premium steak-based restaurant groups

German Doner Kebab ("GDK")

Advised Hero Brands on the strategic investment in GDK by True. GDK is a leading Middle Eastern quick-service restaurant brand, with over 145 franchised locations in the UK and 170 globally, including the US, Canada, Sweden and the Middle East

UK High Street business of WH Smith PLC

Advising WH Smith PLC, one of the UK’s leading retailers, on the sale of its UK High Street business

Pacific Smiles Group

Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover

Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)

Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)

Robertet SA

Advising Fonds Stratégique de Participations and Peugeot Invest SA, on the acquisition of a 14% stake for €250 million in Robertet SA, world leader in natural products, from DSM-Firmenich AG

Centogene GmbH

Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
Haleon plc’s Nicotine Replacement Therapy Business (ex-US)

Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories

CP Kelco

Advising Tate & Lyle plc, a UK-listed specialty food and beverage ingredients company, on the acquisition of CP Kelco, a US-based provider of pectin, speciality gums and other nature-based ingredients, from J.M. Huber Corporation

Functional Formularies

Advised Danone on its acquisition of Functional Formularies, a leading whole foods tube feeding business in the US, from Swander Pace Capital

Tegra’s Operating Entities in Honduras, El Salvador, and the U.S.

Advising Tegra, a premier and leading near and onshore apparel manufacturer for sport, team, and performance apparel, on the sale of its operating entities in Honduras, El Salvador, and the U.S. to SAE-A Trading, a vertically integrated textile and apparel garment manufacturer

myHomecare Group

Advising Australian Unity on its acquisition of myHomecare Group

Exit of Homesafe Equity Release Joint Venture

Adviser to Bendigo and Adelaide Bank on the exit of its investment in the Homesafe Equity Release Joint Venture

Clinigen Ltd’s portfolio of Established Medicines

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

Farmalider Group

Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH

Juice Plus+

Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction

Australian Unity Diversified Property Fund

Advising Australian Unity Property Limited, as the responsible entity of the Australian Unity Diversified Property Fund, on Australian Unity Diversified Property Fund’s merger with Cromwell Direct Property Fund

Lookers Plc

Advising JerseyCo, the indirect Holdco of Alpha Auto Group, a Canadian automotive dealership group, on its acquisition of Lookers Plc, a leading UK automotive dealership group

Marley Spoon business combination with 468 SPAC II

Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

Clinigen Ltd’s Lamda Laboratories

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

Flavor Specialty Ingredients division of IFF

Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market

Clinigen Ltd’s Proleukin

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

Kyowa Kirin International’s established medicines business

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company